

## NEW ORTHO BIOTECH AGREEMENT FOR DOXIL AND PROCRIT

**Effective July 1, 2005** Oncology Associates offers a new agreement for Doxil (doxorubicin HCl liposome injection) and PROCRIT (Epoetin alfa). The new agreement will run **until June 30, 2007**. All OA Members in good standing are eligible and do not need to take action in order to receive these benefits.



**DOXIL** is offered in **20 mg and 50 mg vials** and is indicated for the treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinum-based chemotherapy regimens.



This indication is based on objective tumor response rates. No results are available from controlled trials that demonstrate a clinical benefit resulting from this treatment, such as improvement in disease-related symptoms or increased survival.

**PROCRIT** is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. PROCRIT is indicated to decrease the need for transfusions in patients who will be receiving concomitant chemotherapy for a minimum of 2 months. PROCRIT is not indicated for the treatment of anemia in cancer patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately.

Please contact Oncology Associates at 888-732-7352 for questions regarding the Ortho Biotech agreement for DOXIL and PROCRIT.

Product Name	Package Size	NDC#	Strength
Doxil	2 mg/ ml (10 ml)	17314-9600-01	2 mg/ml
Doxil	2 mg/ml (25 ml)	17314-9600-02	2 mg/ml

## OCTREOTIDE ACETATE INJECTION ADDED TO BEDFORD AGREEMENT

Effective April 4, 2005, Octreotide Acetate Injection has been added to the Bedford Laboratories agreement.



"In our continuing effort to offer the most comprehensive line of oncology and oncology adjunct products in the multisource industry, Bedford Laboratories is once again very pleased to be the first generic alternative to market with this very important product," said Dave Gaugh, General Manager of Bedford Laboratories.

Bedford Laboratories will provide Octreotide Acetate Injection in five presentations: 50 mcg/1mL, 100 mcg/1mL, 500 mcg/1mL, 200mcg/mL, 5mL, and 1mg/mL 5mL octreotide (as acetate).

Octreotide Acetate Injection is used to treat patients with acromegaly and to control symptoms, such as severe diarrhea and flushing, in patients with functional gastro-entero-pancreatic (GEP) tumors (e.g. metastatic carcinoid tumors and vasoactive intestinal peptide-secreting tumors [VIPomas]).

OCTREOTIDE ACETATE INJECTION – PRESERVATIVE FREE			
NDC Number	Product Description	Fill Volume	Unit of Sale
55390-160-10	50 mcg/1 mL SD Vial	1 mL	10
55390-161-10	100 mcg/1 mL SD Vial	1 mL	10
55390-162-10	500 mcg/1 mL SD Vial	1 mL	10
OCTREOTIDE ACETATE INJECTION – PRESERVED			
NDC Number	Product Description	Fill Volume	Unit of Sale
55390-163-01	200 mcg/1 mL MD Vial	5 mL	1
55390-164-01	1000 mcg/1 mL MD Vial	5 mL	1

## WYETH CONTRACT REMINDER FOR NEUMEGA®

Oncology Associates would like to remind you of its contract for Neumega®. The agreement provides valuable savings for the product Neumega® in 5 mg vials and 5 mg vials in 7/box quantities.



Neumega® is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are high risk of severe thrombocytopenia.

Please contact your local Wyeth representative or call OA at **888-732-7352** for more information about the agreement for Neumega®.